Search
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigationalconsiderable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over
Activated charcoal
go.drugbank.com/drugs/DB09278ApprovedInvestigationalIt is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalDevelopment was discontinued due to concerns over hepatotoxicity observed in animal studies.
Melatonin
go.drugbank.com/drugs/DB01065ApprovedInvestigationalNutraceuticalVet approvedMelatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the ...
NGX267
go.drugbank.com/drugs/DB05152InvestigationalNGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Varlitinib
go.drugbank.com/drugs/DB05944InvestigationalOver-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigationalSevere acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigational[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago.